Despite initial promise in pre-clinical models, reports regarding the efficacy of androgen-targeted therapies in prostate cancer patients harboring TMPRSS2-ERG gene fusions have not been conclusive (59, 60). This evidence concerns the gene ERG and prostate carcinoma.